MIST Earnings

MIST reported its earnings on 2026-05-13, showcasing a revenue of 238.00K against an estimate of 75.08M, resulting in a -99.68% surprise. The EPS was -0.2, surpassing the expected -0.03 by -566.67%. The stock experienced a -9.47% price change on the earnings day and a -23.16% change over the next five days, reflecting market reactions to the results.

Following MIST's earnings announcement on 2026-05-13, the stock price moved by -9.47% on the day of the release. Over the subsequent five days, it saw a -23.16% change. Historically, MIST's stock price tends to shift by an average of -3.23% in the 10 days leading up to earnings and 4.99% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate MIST's annual revenue to reach 911.25K, while the EPS is projected at -0.24. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MIST's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MIST's stock price typically moves by -3.23% in the 10 days before its earnings and 4.99% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.24 and revenue of 911.25K.

The earnings call reveals several concerns: low revenue, increased commercial expenses, and a significant net loss. Despite positive elements like reduced R&D and G&A expenses, and an Express Scripts agreement, the Q&A highlights uncertainties, especially regarding prescription volume and payer coverage. The lack of clear guidance on free drug distribution and payer expansion further clouds the outlook. Overall, the financial strain and ambiguous responses suggest a negative sentiment, likely impacting the stock price negatively in the short term.